TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02939742

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betamethasone
Description: Betamethasone 12mg IM given every 24 hours for two doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile 0.9% normal saline solution given IM every 24 hours for two doses
Study: NCT02206906

Intervention type: BEHAVIORAL
Intervention: Incentive intervention model
Description: All participants will receive a real-time electronic medication monitor to monitor daily pill-taking behavior. Participants with qualifying levels of adherence will receive a weekly incentive during the intervention period. At all clinic visits participants will participate in a lottery incentive to reinforce clinic attendance and negative STI screening tests.
Study: NCT01220999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-1008
Description: CS-1008 was administered once weekly as an intravenous infusion over 30 ± 10 minutes at a dose range of 0.2 to 6 mg/kg. On Days 1 and 36, CS-1008 infusions were radiolabeled with 111\^In (5-7 mCi).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-1008
Description: CS-1008 was administered once weekly as an intravenous infusion over 30 ± 10 minutes at a dose range of 0.2 to 6 mg/kg. On Days 1 and 36, CS-1008 infusions were radiolabeled with 111\^In (5-7 mCi).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-1008
Description: CS-1008 was administered once weekly as an intravenous infusion over 30 ± 10 minutes at a dose range of 0.2 to 6 mg/kg. On Days 1 and 36, CS-1008 infusions were radiolabeled with 111\^In (5-7 mCi).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-1008
Description: CS-1008 was administered once weekly as an intravenous infusion over 30 ± 10 minutes at a dose range of 0.2 to 6 mg/kg. On Days 1 and 36, CS-1008 infusions were radiolabeled with 111\^In (5-7 mCi).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CS-1008
Description: CS-1008 was administered once weekly as an intravenous infusion over 30 ± 10 minutes at a dose range of 0.2 to 6 mg/kg. On Days 1 and 36, CS-1008 infusions were radiolabeled with 111\^In (5-7 mCi).
Study: NCT06506552

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: IMA preserving
Description: Performing left hemicolectomy, sigmoidectomy or rectal resection the IMA was preserved ligating the sigmoids arteries close to the colonic wall

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IMA sectioning
Description: Performing left emicolectomy, sigmoidectomy or rectal resection the IMA is sectioned after the origin of left colic artery.
Study: NCT01263522

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: different training programs
Description: two different endurance programs and one strength endurance program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: different training programs
Description: two different endurance programs and one strength endurance program

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: different training programs
Description: two different endurance programs and one strength endurance program

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control condition
Description: unchanged lifestyle
Study: NCT02527694

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flexible EMS stretcher cart
Description: The flexible EMS stretcher cart is an innovative EMS stretcher cart built to be flexible to fit in smaller spaces such as elevators. The flexible stretcher bends at the hip joint as well as at the knee joint, so that the patient can be put in head-up position at 30 degrees elevation with elevated legs.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: mechanical CPR
Study: NCT00085189

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: agatolimod sodium
Description: Given SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: agatolimod sodium
Description: Given SC

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00925522

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Therapy Cool Path Duo Cardiac Ablation System
Description: Cardiac Ablation Procedure for Ischemic VT using a flexible, insulated 7F all braided catheter that contains an internal lumen connected to 12 open conduits at the 4mm tip electrode for infusion of heparinized saline during radiofrequency ablation; records intracardiac electrograms and can be utilized for cardiac simulation during diagnostic electrophysiologic studies/evaluation.~1500T9-VT generator is a microprocessor-controlled device that produces a continuous unmodulated radiofrequency (RF) output of 485 kHz. The Generator will be used in Temperature Control mode only. The catheter delivers the RF power from the generator in a monopolar mode between its distal electrode (tip electrode) and a large indifferent electrode.
Study: NCT02469506

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromuscular Electrical Stimulation (NMES)
Description: The protocol will consist of a warm-up period (5 min), a stimulation period (30min), and a cooling-down period (5min). Stimulation will be provided by an Enraf Nonius TensMed S84 stimulation device.
Study: NCT01825811

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TissueGene-C (Low dose)
Description: TissueGene-C at 1.0 x 10\^6 cells mixed with fibrin-glue

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TissueGene-C (High dose)
Description: TissueGene-C at 3.0 x 10\^6 cells mixed with fibrin-glue
Study: NCT01861158

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parenting Wisely
Description: Computer-based, online, interactive parenting intervention

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Parenting Wisely
Description: Computer-based, online, interactive parenting intervention
Study: NCT01729065

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy intervention
Description: Exercises addressing cervical range of motion, shoulder range of motion and strengthening and scapular stabilization.
Study: NCT03961724

Intervention type: DEVICE
Intervention: magnetic resonance image (MRI)
Description: serum metabolomics

Intervention type: DEVICE
Intervention: magnetic resonance image (MRI)
Description: serum metabolomics
Study: NCT01657760

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: citalopram
Description: citalopram, 40 mg IV, vs. saline control, each to be administered in a double-blinded, within-subjects design.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: citalopram
Description: citalopram, 40 mg IV, vs. saline control, each to be administered in a double-blinded, within-subjects design.
Study: NCT03071523

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: coronally advanced lingual flap
Description: Full-thickness crestal incision will be made over the edentulous ridge followed by one full-thickness vertical incision on the buccal side. On the buccal side, full thickness mucoperiosteal flap will be raised with horizontal incision 1-3 mm in depth performed in the buccal flap. On the lingual side, a full-thickness mucoperiosteal flap will be elevated until reaching the mylohyoid line. A band of mylohyoid muscle is inserted into the inner part of the lingual flap approximately 5 mm from the crest in an apical direction. A blunt instrument will be inserted below that connective band, and, with gentle traction in the coronal direction, this muscular insertion should be detached freeing the lingual flap from the mylohyoid.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: periosteal releasing incision
Description: Full-thickness crestal incision will be made over the edentulous ridge followed by one full-thickness vertical incision on the buccal side and a full thickness flap will be raised. Xenograft and Ti-mesh will be used to augment the defective site then incremental incisions of 1-3 mm into the periosteum and submucosa will be used to advance the muco-periosteal flap. The flap will then be sutured with interrupted sutures.
Study: NCT02081976

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Integrated Care Group
Description: The group (TG) consisted of periodontal treatment comprising one session of supragingival scaling and personalized oral hygiene instructions, followed by one to four sessions of subgingival scaling and root planing (SRP) by quadrant, under local anesthesia, in a period of 14 days. Individuals were be followed monthly during the first 6 months. In the follow-up sessions, professional plaque removal, oral hygiene instructions, cardiac support along with counseling reinforcement were be provided.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care Group
Description: The group (TG) comprising one session of supragingival scaling followed by one to four sessions of subgingival scaling and root planing (SRP) by quadrant, under local anesthesia, in a period of 14 days.
Study: NCT03989609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine Injection [Precedex]
Description: Dexmedetomidine infusion will be started at 0.1 µg.kg-1.hr-1 and will be adjusted by 0.1 µg.kg-1.h-1 to a maximum of 0.5 µg/kg/h,

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: midazolam will be started at 1 mg.h-1 (3 mL.hr-1) and adjusted by 1 mg.h-1 to a maximum of 5 mg.h-1 (15 mL.h-1).
Study: NCT02589613

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: tap water
Description: 300ml tap water via nasogastric tube

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: 300ml tap water with 75g Glucose via nasogastric tube

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Fructose
Description: 300ml tap water with 25g Fructose via nasogastric tube
Study: NCT02570100

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biological collection
Description: Collection of blood samples and tumor specimens :~Biological collection before treatment :~* 1 tumor specimen (under echographic control)~* 4 blood collections~Biological collection during treatment :~* 1 tumor specimen after 3 cycles~* 4 blood collections after 3 and 6 cycles
Study: NCT01083966

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab (Avastin)
Description: Super-Selective Intraarterial Intracranial Infusion of Bevacizumab in Vestibular Schwannoma~This phase I clinical research trial will test the hypothesis that Bevacizumab can be safely used by direct intracranial superselective intraarterial infusion up to a dose of 10mg/kg to ultimately enhance survival and hearing function of patients with VS
Study: NCT02562521

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contingency management
Description: Participants in the intervention group will receive a tailored intervention that utilizes contingency management in which they receive monetary rewards for reducing or quitting smoking.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine replacement therapy
Description: Participants have the option of using nicotine patch in combination with nicotine gum or lozenge

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varenicline
Description: Individuals who do not respond initially to Nicotine Replacement Therapy will be offered varenicline as an alternative

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Additional behavioral support
Description: Based on interest, participants can be referred to a telephone quitline or receive access to mobile text messaging programs or app based smoking cessation support
Study: NCT01122134

Intervention type: DRUG
Intervention: intravenous artesunate
Description: Intravenous artesunate in a dose of 2.4 mg/kg at start of treatment, 2.4 mg/kg 12 hours later and 2.4 mg/kg/day until the patient is able to tolerate oral therapy. The minimum duration of IV treatment will be 24 hours.
Study: NCT03482999

Intervention type: DEVICE
Intervention: TissuGlu Surgical Adhesive
Study: NCT02053506

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Immune-enhancing nutritional beverage
Description: Combination of arginine, glutamine, omega-3 fatty acids, vitamin C and zinc.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics (BB-12)
Description: Probiotics (Bifidobacterium Animalis Lactis, BB-12®, Chr Hansen A/S, Hoersholm, Denmark) will be administered as a strawberry-flavored, powdered candy (1 g). The candy will be packaged in a small foil pouch, and each pouch will contain approximately 1 billion colony forming units (CFU) of BB-12® in powder form.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo (for nutritional beverage and probiotic)
Description: Dietary protein at RDA of 0.8 grams•kg-1 body weight•day-1 and a placebo beverage during and after the period of sleep restriction.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo (for nutritional beverage and probiotic)
Description: Dietary protein at RDA of 0.8 grams•kg-1 body weight•day-1 and a placebo beverage during and after the period of sleep restriction.
Study: NCT00983294

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchicine
Description: A single dose of 0.6 mg colchicine administered alone at 7:30 am on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: Two 250 mg azithromycin tablets administered at 7:30 am on Day 15, then one 250 mg tablet administered daily at 7:30 am on Days 16 to 19.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colchicine
Description: A single dose of 0.6 mg colchicine administered with azithromycin at 7:30 am on Day 19.
Study: NCT03093064

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Natalizumab
Description: Natalizumab is a humanized monoclonal antibody against the cell adhesion molecule α4-integrin, currently licensed for the treatment of multiple sclerosis and Crohn's disease.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: normal saline
Description: Normal saline, intravenous infusion
Study: NCT02646098

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CD34+ cell selection
Description: CD34+ cell selection applying a CliniMACS device (Miltenyi Biotec, Bergisch Gladbach, Germany). This method for CD34+ cell selection will be used in this study and is considered as the standard treatment.
Study: NCT02588521

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-794

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo/Vehicle
Description: Suspension vehicle without active drug
Study: NCT01930188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: For subcutaneous injection (s.c., under the skin) once weekly. Will follow a fixed dose escalation regimen. The trial drug will be added on to the subject's stable pre-trial medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: semaglutide
Description: For subcutaneous injection (s.c., under the skin) once weekly. Will follow a fixed dose escalation regimen. The trial drug will be added on to the subject's stable pre-trial medication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin
Description: Tablets for oral administration once daily. The trial drug will be added on to the subject's stable pre-trial medication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sitagliptin
Description: Tablets for oral administration once daily. The trial drug will be added on to the subject's stable pre-trial medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Tablets for oral administration once daily. The trial drug will be added on to the subject's stable pre-trial medication.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Tablets for oral administration once daily. The trial drug will be added on to the subject's stable pre-trial medication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: For subcutaneous injection (s.c., under the skin) once weekly. Will follow a fixed dose escalation regimen. The trial drug will be added on to the subject's stable pre-trial medication.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: For subcutaneous injection (s.c., under the skin) once weekly. Will follow a fixed dose escalation regimen. The trial drug will be added on to the subject's stable pre-trial medication.
Study: NCT03770897

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D Laparoscopic Appendectomy
Description: surgical removal of inflamed cecal appendix by 3D laparoscopic procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: 2D Laparoscopic Appendectomy
Description: surgical removal of inflamed cecal appendix by 2D laparoscopic procedure
Study: NCT00879827

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pediarix TM, Infanrix penta TM
Description: The vaccines were administered according to a 3-dose schedule at 1.5, 3.5 and 6 months of age.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hiberix TM
Description: The vaccines were administered according to a 3-dose schedule at 1.5, 3.5 and 6 months of age.
Study: NCT02764320

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Migraine Prophylactic Therapy Only
Description: Start of new migraine preventive therapy or adjustment of current preventive therapy without immediate discontinuation of the overused medication(s)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Discontinuation of Overused Medication
Description: Immediate discontinuation of the overused medication(s) and the start of new migraine preventive therapy or adjustment of current preventive therapy
Study: NCT00986505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Intravenous lidocaine once a week
Study: NCT02383797

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Varilrix
Description: Vaccination against varicella in selected cartilage-hair hypoplasia patients
Study: NCT03392844

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beds for Kids program
Description: The Beds for Kids program, which is part of the non-profit organization One House at a Time, gives every child in the program a new twin-size bed mattress, metal bed frame, and a bedtime bag, which contains a sheet set, blanket, pillow, several books, stuffed animal, and toothbrush. Children also receive educational messages about healthy sleep habits via a magnet and color-your-own bookmark. All of the items are sorted, packaged, and delivered directly to program recipients in their homes.
Study: NCT02625870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omega-3-Acid Ethyl Esters 90 Soft Capsules
Description: Omega-3-Acid Ethyl Esters 90 Soft Capsules will be provided in 1 g polyacrylate-coated soft gel capsules.Four capsules will be taken with breakfast once per day, for 12 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Corn Oil
Description: Corn Oil will be provided in 1 g polyacrylate-coated soft gel capsules.Four capsules will be taken with breakfast once per day, for 12 weeks.
Study: NCT01579955

Intervention type: DRUG
Intervention: eptacog alfa (activated)
Description: Prescription of eptacog alpha at the discretion of the physician
Study: NCT05303324

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1840
Description: Participants received ALXN1840 at Hour 0 on Day 1 of the dosing period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALXN1840
Description: Participants received ALXN1840 at Hour 0 on Day 1 of the dosing period.
Study: NCT02125565

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Injected subcutaneous local (lidocaine) anaesthesia
Description: Trial of technique
Study: NCT03944889

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sonosite Ultrasound Machine
Description: Ultrasound System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sonosite Ultrasound Machine
Description: Ultrasound System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sonosite Ultrasound Machine
Description: Ultrasound System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sonosite Ultrasound Machine
Description: Ultrasound System

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sonosite Ultrasound Machine
Description: Ultrasound System
Study: NCT02704689

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AccuLIF expandable TLIF cage
Description: AccuLIF TL expandable interbody cage used with autogenous bone and/or allograft (cancellous or corticocancellous allograft chips) and supplemental fixation.
Study: NCT05093803

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CONTROL GROUP
Description: Intervention based on measurements of health parameters before and after providing participants with personalized dietary and physical activity recommendations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HEALTH APP GROUP
Description: Use of a mobile application based on machine learning with the aim of improving health parameters and body composition.~Specific diet program and moderate physical activity, all guided and mediated by a mobile application. As well as the recording and monitoring of periodic evaluations of health indicators.
Study: NCT00828152

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-delivered CBT.
Description: 12 weeks. Therapist contact through e-mail.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: On line discussion group
Description: Placebo. On line discussion group.
Study: NCT00004263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 7-hydroxystaurosporine (UCN-01)
Description: 20 mg/m2 IV over 24 hours on days 2-4 of course 1 and over 36 hours beginning on day 2 of subsequent courses. Treatment repeats every 4 weeks for a maximum of 4 courses.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine (Ara-C)
Description: Starting dose 1 g/m2 IV over 24 hours on days 1-4 of each course. Treatment repeats every 4 weeks for a maximum of 4 courses.
Study: NCT04464070

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: niacin
Description: induce biosynthesis of PGD2

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: niacin
Description: induce biosynthesis of PGD2

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: niacin
Description: induce biosynthesis of PGD2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin
Description: inhibition of cyclooxygenase

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin
Description: inhibition of cyclooxygenase